Effect of the GLP ‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial

Documenti analoghi

• Effects of GLP‐1 Receptor Agonists in Alcohol Use Disorder
  di: Mette Kruse Klausen, et al.
  Pubblicazione: (2025)
• Blood phosphatidylethanol measurements indicate GLP ‐1 receptor stimulation causes delayed decreases in alcohol consumption
  di: Mathias E. Jensen, et al.
  Pubblicazione: (2025)
• How to treat antipsychotic‐related weight gain and metabolic disturbances: Is there a role for GLP ‐1 receptor agonists?
  di: Anders Fink‐Jensen, et al.
  Pubblicazione: (2024)
• Liraglutide 3.0 mg once daily for the treatment of overweight and obesity in patients hospitalised at a forensic psychiatric department: A 26‐week open‐label feasibility study
  di: Marie Reeberg Sass, et al.
  Pubblicazione: (2024)
• Acute effects of GIP and GLP ‐1 receptor antagonism in totally pancreatectomized individuals: A randomized double‐blind, placebo‐controlled crossover study
  di: Liva S. L. Krogh, et al.
  Pubblicazione: (2025)